The latest price target for Reshape Lifesciences (NASDAQ:RSLS) was reported by Maxim Group on July 17, 2024. The analyst firm set a price target for $0.00 expecting RSLS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Reshape Lifesciences (NASDAQ:RSLS) was provided by Maxim Group, and Reshape Lifesciences downgraded their hold rating.

There is no last upgrade for Reshape Lifesciences

The last downgrade for Reshape Lifesciences Inc happened on July 17, 2024 when Maxim Group changed their price target from N/A to N/A for Reshape Lifesciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reshape Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reshape Lifesciences was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.

While ratings are subjective and will change, the latest Reshape Lifesciences (RSLS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Reshape Lifesciences (RSLS) is trading at is $5.51, which is out of the analyst’s predicted range.